Therini Bio has started dosing patients in a Phase 1b trial for THN391, a novel antibody targeting fibrin-driven inflammation in diabetic macular edema (DME). This therapy aims to reduce neuroinflammation and retinal degeneration without affecting blood clotting. The trial will test safety and efficacy across three dose levels, with initial results expected in late 2026. Additionally, Therini is advancing THN622, a bispecific antibody combining anti-fibrin and anti-VEGF actions, potentially improving treatment outcomes for retinal diseases including DME.
ResVR has introduced an AI-powered assistant integrated into its 3D virtual homebuying platform, enabling buyers to navigate, customize, and make decisions with real-time voice interaction. This assistant offers 24/7 support, multi-language accessibi...
Privia Health Group, a national physician enablement company, announced its expansion into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a large neurology practice with 25 clinicians. NGBC will anchor the new Privia M...
Matlantis has introduced an AI agent integration using Anthropic's Claude Code to its atomistic simulation platform, allowing researchers to create and run simulations via natural language. This innovation removes the scripting barrier in computation...
AsymBio, a biologics CDMO, introduced its Conjugation Toolbox to support customized and scalable process development for next-generation bioconjugates like antibody-drug conjugates (ADCs). This platform offers flexible conjugation methods, including ...
JenaValve Technology, Inc. has appointed Edward Sarnowski as Chief Technology Officer to lead its research and development efforts. This move follows the recent FDA approval of JenaValve's Trilogy Transcatheter Heart Valve System, designed to treat s...
